This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Clindamycin phosphate parenteral

Updated 2 Feb 2023 | Clindamycin


Solution for injection or infusion containing clindamycin (as clindamycin phosphate)

Drugs List

  • clindamycin 300mg/2ml injection
  • clindamycin 300mg/50ml infusion bag
  • clindamycin 600mg/4ml injection
  • clindamycin 600mg/50ml infusion bag
  • DALACIN C PHOSPHATE 300mg/2ml injection
  • DALACIN C PHOSPHATE 600mg/4ml injection
  • Therapeutic Indications


    Severe antibiotic sensitive infections

    Treatment of serious infections caused by:
    Susceptible Gram positive organisms, staphylococci (both penicillinase- and non-penicillinase producing)
    Streptococci (except Streptococcus faecalis)
    Susceptible anaerobic pathogens such as Bacteroides spp, Fusobacterium spp, Propionbacterium spp, Peptostreptococcus spp and microaerophilic streptococci

    Clindamycin does not penetrate the blood/brain barrier in therapeutically effective quantities.


    Treatment for infections caused by beta-haemolytic streptococci should be continued for at least 10 days to guard against subsequent rheumatic fever or glomerulonephritis.


    Solution for injection or infusion
    Serious infections
    600 to 1200mg/day in two, three or four equal doses.

    More severe infections
    1200 to 2700mg/day in two, three or four equal doses.

    Infusion bags
    Serious infections
    1200 to 1800mg/day in two, three or four equal doses.

    More severe infections
    1800 to 2700mg/day in two, three equal doses.

    For more serious infections, these doses may have to be increased. In life-threatening situations, doses as high as 4.8g daily have been given intravenously to adults.


    Not all products are licensed for use in children under 12 years.

    Solution for injection or infusion
    Children 1 month to 18 years
    Serious infections
    15 to 25mg/kg/day in three or four equal doses.

    More severe infections
    25 to 40mg/kg/day in three or four equal doses. In severe infections it is recommended that children be given at least 300mg/day regardless of body weight.


    For intravenous infusion or intramuscular injection.

    Intramuscular injection
    Single intramuscular injections of greater than 600mg are not recommended.

    Irritation, pain, and abscess formation at the intramuscular injection site can be minimised by administering the product by deep intramuscular injection.

    Intravenous infusion
    Solution for injection or infusion
    Clindamycin phosphate must be diluted prior to intravenous administration should be infused over at least 10 to 60 minutes.
    Administration of more than 1.2g in a single one hour infusion is not recommended.
    The drug may be administered in the form of a single rapid infusion of the first dose followed by continuous intravenous infusion.

    The concentration of clindamycin in diluent for intravenous infusion should not exceed 18mg/ml and infusion rates should not exceed 30mg/minute.

    Infusion rates are as follows:
    A dose of 300mg in 50ml of diluent should be infused over 10 minutes.
    A dose of 600mg in 50ml of diluent should be infused over 20 minutes.
    A dose of 900mg in 50 to 100ml of diluent should be infused over 30 minutes.
    A dose of 1200mg in 100ml of diluent should be infused over 40 minutes.

    Thrombophlebitis at the intravenous injection site can be minimised by avoiding the use of an indwelling catheter.

    Infusion bags
    Clindamycin phosphate does not require further dilution and should be infused over at least 10 to 60 minutes.


    Neonates under 1 month

    Precautions and Warnings

    Children under 12 years
    Hypersensitivity to benzyl alcohol
    Restricted sodium intake
    Glucose-galactose malabsorption syndrome
    Hepatic impairment
    History of colitis
    History of gastrointestinal disorder
    Neuromuscular disorder
    Renal impairment

    Some formulations contain more than 1mmol (23mg) sodium per dose
    Advise ability to drive/operate machinery may be affected by side effects
    Consult national/regional policy on the use of anti-infectives
    Not all available products are licensed for all age groups
    Some formulations contain glucose
    Some presentations may contain benzyl alcohol
    Monitor haematological status during prolonged and high dose therapy
    Monitor hepatic function on long term therapy
    Monitor renal and hepatic function in infants
    Monitor renal function on long term therapy
    Advise patient to inform physician if/when (delayed) diarrhoea occurs
    Consider pseudomembranous colitis if patient presents with diarrhoea
    Prolonged use may result in superinfection with non-susceptible organisms
    Discontinue if severe skin reaction occurs
    Discontinue immediately if diarrhoea occurs

    Clindamycin phosphate should only be used in the treatment of serious infections. In considering the use of the product, the practitioner should bear in mind the type of infection and the potential hazard of the diarrhoea (including Clostridium difficile associated diarrhoea) which may develop. Cases of colitis have been reported during, or even 2 or 3 weeks following the administration of clindamycin.

    Pregnancy and Lactation


    Use clindamycin with caution during pregnancy.

    The manufacturer advises clindamycin should only be administered during pregnancy if the potential benefit outweighs the possible risk to the foetus. Schaefer suggests clindamycin is only indicated during pregnancy when penicillins, cephalosporins, erythromycin or the other macrolides are not effective. Inadvertent use is not an indication for termination of pregnancy or for additional prenatal diagnostic procedures (Schaefer 2007). Animal studies indicate that there is no evidence of reproductive toxicity.

    Clindamycin crosses the placenta. After multiple dosing the foetal tissue levels of clindamycin increase, with the drug concentrating in the foetal liver.


    Use clindamycin with caution during breastfeeding.

    The manufacturer does not recommend breastfeeding whilst taking clindamycin. Clindamycin is present in human breast milk. Effects on exposed infants is unknown, but there is potential for serious adverse reactions.

    Side Effects

    Abdominal pain
    Abnormal liver function tests
    Abscess formation (injection site)
    Acute generalised exanthematous pustulosis
    Anaphylactic reaction
    Anaphylactoid reaction
    Antibiotic-associated colitis
    Cardiac arrest
    Drug rash with eosinophilia and systemic symptoms (DRESS)
    Erythema multiforme
    Exfoliative dermatitis
    Hypersensitivity reactions
    Induration (injection site)
    Irritation (injection site)
    Local pain (injection site)
    Maculopapular rash
    Morbilliform-like skin rashes
    Oesophageal ulceration
    Stevens-Johnson syndrome
    Thrombophlebitis (injection site)
    Toxic epidermal necrolysis
    Vesiculo-bullous reactions


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: February 2020

    Reference Sources

    Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 2nd edition (2007) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London.

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 9th edition (2011) ed. Briggs, G., Freeman, R. and Yaffe, S. Lippincott Williams & Wilkins, Philadelphia.

    Medications and Mothers' Milk, 14th Edition (2010) Hale, T. Hale Publishing, Amarillo, Texas.

    Summary of Product Characteristics: Clindamycin 300mg/50ml solution for infusion. Bowmed Ibisqus Ltd. Revised April 2019.
    Summary of Product Characteristics: Clindamycin 600mg/50ml solution for infusion. Bowmed Ibisqus Ltd. Revised April 2019.
    Summary of Product Characteristics: Clindamycin 150 mg/ml solution for injection or infusion. Focus Pharmaceuticals. Revised May 2018.
    Summary of Product Characteristics: Dalacin C Phosphate Sterile Solution. Pfizer Limited. Revised December 2018.

    NICE Evidence Services Available at: Last accessed: 25 February 2020

    US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
    Available at:
    Clindamycin Last revised: 31 October 2018
    Last accessed: 24 February 2020

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.